High probability suggests strong belief in epigenetic pathways improving neural graft survival.
The market shows an 80.50% probability for the positive outcome, indicating significant confidence in the role of epigenetic reprogramming in enhancing neural graft survival. The Pulse AI probability aligns closely, reinforcing the market's assessment, though the edge suggests it is fairly priced. With a confidence rating of 55/100 and 98 hours until expiry, there is moderate uncertainty surrounding the outcome.